The influence of pretreatment with ghrelin on the development of acetic-acid-induced colitis in rats

Journal of Physiology and Pharmacology

Volumn 66, Issue 6, 2015, Pages 875-885

  Maduzia, D ^a   Matuszyk, A ^a   Ceranowicz, D ^a   Warzecha, Z ^a   Ceranowicz, Piotr ^a   Fyderek, K ^a   Galazka, K ^a   Dembinski, A ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Colitis; Colonic blood flow; DNAsynthesis; Ghrelin; Interleukin 1 ; Malondialdehyde; Myeloperoxidase; Oxidative stress

Indexed keywords

ACETIC ACID; ENEMA; GHRELIN; INTERLEUKIN 1BETA; MALONALDEHYDE; MYELOPEROXIDASE; SUPEROXIDE DISMUTASE; DNA; PEROXIDASE; PROTECTIVE AGENT;

ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD FLOW; CONTROLLED STUDY; DNA SYNTHESIS; EXPERIMENTAL COLITIS; HISTOLOGY; INFLAMMATION; LIPID PEROXIDATION ASSAY; MALE; NONHUMAN; RAT; ANIMAL; BIOSYNTHESIS; CHEMICALLY INDUCED; COLITIS; COLON; DRUG EFFECTS; INTESTINE MUCOSA; METABOLISM; PATHOLOGY; VASCULARIZATION; WISTAR RAT;

ACETIC ACID; ANIMALS; COLITIS; COLON; DNA; GHRELIN; INTERLEUKIN-1BETA; INTESTINAL MUCOSA; MALE; MALONDIALDEHYDE; PEROXIDASE; PROTECTIVE AGENTS; RATS, WISTAR; REGIONAL BLOOD FLOW; SUPEROXIDE DISMUTASE;

EID: 84954490191     PISSN: 08675910     EISSN: 18991505     Source Type: Journal    
DOI: None     Document Type: Article

References (70)

1. Stenson WF, Hanauer SB, Cohen RD. Inflammatory bowel disease. In: Textbook of Gastroenterology, Yamada T, Alpers DH, Kalloo AN, Kaplowitz N, Owyang C, Powell DW (eds). Chichester, Wiley-Blackwell, 2009, pp. 1386-1472.
2. Tsironi E, Feakins RM, Probert CS, Rampton DS, Phil D. Incidence of inflammatory bowel disease is rising and abdominal tuberculosis is falling in Bangladeshis in East London, United Kingdom. Am J Gastroenterol 2004; 99: 1749-1755.
3. Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012; 142: 46-54.
4. Ng SC, Bernstein CN, Vatn MH, et al. Geographical variability and environmental risk factors in inflammatory bowel disease. Gut 2013; 62: 630-649.
5. Ng SC, Tang W, Leong RW, et al. Environmental risk factors in inflammatory bowel disease: a population-based case-control study in Asia-Pacific. Gut 2015; 64: 1063-1071.
6. Baumgart DC. The diagnosis and treatment of Crohn’s disease and ulcerative colitis. Dtsch Arztebl Int 2009; 106: 123-133.
7. Baumgart DC, Sandborn WJ. Crohn’s disease. Lancet 2012; 380 (9853):1590-1605.
8. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone releasing acylated peptide from stomach. Nature 1999; 402: 656-660.
9. Ariyasu H, Takaya K, Tagami T, et al. Stomach is a major source of circulating ghrelin, and feeding state determines plasma ghrelin-like immunoreactivity levels in humans. J Clin Endocrinol Metab 2001; 86: 4753-4758.
10. Ceranowicz P, Warzecha Z, Dembinski A. Peptidyl hormones of endocrine cells origin in the gut – their discovery and physiological relevance. J Physiol Pharmacol 2015; 66: 11-27.
11. Gnanapavan S, Kola B, Bustin SA, et al. The tissue distribution of the mRNA of ghrelin and subtypes of its receptor, GHS-R, in humans. J Clin Endocrinol Metab 2002; 87: 2988-2991.
12. Tschop M, Flora DB, Mayer JP, Heiman ML. Hypophysectomy prevents ghrelin-induced adiposity and increases gastric ghrelin secretion in rats. Obes Res 2002; 10: 991-999.
13. Dixit VD, Schaffer EM, Pyle RS, et al. Ghrelin inhibits leptin- and activation-induced proinflammatory cytokine expression by human monocytes and T cells. J Clin Invest 2004; 114: 57-66.
14. Sibilia V, Rindi G, Pagani F, et al. Ghrelin protects against ethanol-induced gastric ulcers in rats: studies on the mechanisms of action. Endocrinology 2003; 144: 353-359.
15. Brzozowski T, Konturek PC, Konturek SJ, et al. Exogenous and endogenous ghrelin in gastroprotection against stress- induced gastric damage. Regul Pept 2004; 120: 39-51.
16. Iseri SO, Sener G, Yuksel M, et al. Ghrelin against alendronate-induced gastric damage in rats. J Endocrinol 2005; 187: 399-406.
17. Ceranowicz P, Warzecha Z, Dembinski A, et al. Treatment with ghrelin accelerates the healing of acetic acid-induced gastric and duodenal ulcers in rats. J Physiol Pharmacol 2009; 60: 87-98.
18. Warzecha Z, Ceranowicz P, Dembinski M, et al. Involvement of cyclooxygenase-1 and cyclooxygenase-2 activity in the therapeutic effect of ghrelin in the course of ethanol-induced gastric ulcers in rats. J Physiol Pharmacol 2014; 65: 95-106.
19. Warzecha Z, Ceranowicz D, Dembinski A, et al. Ghrelin accelerates the healing of cysteamine-induced duodenal ulcers in rats. Med Sci Monit 2012; 18: BR181-BR187.
20. Warzecha Z, Kownacki P, Ceranowicz P, Dembinski M, ieszkowski J, Dembinski A. Ghrelin accelerates the healing of oral ulcers in non-sialoadenectomized and sialoadenectomized rats. J Physiol Pharmacol 2013; 64: 657-668.
21. Dembinski A, Warzecha Z, Ceranowicz P, et al. Ghrelin attenuates the development of acute pancreatitis in rats. J Physiol Pharmacol 2003; 54: 561-573.
22. Dembinski A, Warzecha Z, Ceranowicz P, et al. Role of growth hormone and insulin-like growth factor-1 in the protective effect of ghrelin in ischemia/reperfusion-induced acute pancreatitis. Growth Horm IGF Res 2006; 16: 348-356.
23. Warzecha Z, Ceranowicz P, Dembinski A, et al. Therapeutic effect of ghrelin in the course of cerulein-induced acute pancreatitis in rats. J Physiol Pharmacol 2010; 61: 419-427.
24. Ceranowicz D, Warzecha Z, Dembinski A, et al. Role of hormonal axis, growth hormone - IGF-1, in the therapeutic effect of ghrelin in the course of cerulein-induced acute pancreatitis. J Physiol Pharmacol 2010; 61: 599-606.
25. Bukowczan J, Warzecha Z, Ceranowicz P, Kusnierz-Cabala B, Tomaszewska R, Dembinski A. Therapeutic effect of ghrelin in the course of ischemia/reperfusion-induced acute pancreatitis. Curr Pharm Des 2015; 21: 2284-2290.
26. Konturek PC, Brzozowski T, Engel M, et al. Ghrelin ameliorates colonic inflammation. Role of nitric oxide and sensory nerves. J Physiol Pharmacol 2009; 60: 41-47.
27. Hosomi S, Oshitani N, Kamata N, et al. Phenotypical and functional study of ghrelin and its receptor in the pathogenesis of Crohn’s disease. Inflamm Bowel Dis 2008; 14: 1205-1213.
28. Karmiris K, Koutroubakis IE, Xidakis C, Polychronaki M, Voudouri T, Kouroumalis EA. Circulating levels of leptin, adiponectin, resistin, and ghrelin in inflammatory bowel disease. Inflamm Bowel Dis 2006; 12: 100-105.
29. Peracchi M, Bardella MT, Caprioli F, et al. Circulating ghrelin levels in patients with inflammatory bowel disease. Gut 2006; 55: 432-433.
30. Ates Y, Degertekin B, Erdil A, Yaman H, Dagalp K. Serum ghrelin levels in inflammatory bowel disease with relation to disease activity and nutritional status. Dig Dis Sci 2008; 53: 2215-2221.
31. Gonzalez-Rey E, Chorny A, Delgado M. Therapeutic action of ghrelin in a mouse model of colitis. Gastroenterology 2006; 130: 1707-1720.
32. Pamukcu O, Kumral ZN, Ercan F, Yegen BC, Ertem D. Anti- inflammatory effect of obestatin and ghrelin in dextransulfate sodium-induced colitis in rats. J Pediatr Gastroenterol Nutr 2013; 57: 211-218.
33. De Smet B, Thijs T, Moechars D, et al. Endogenous and exogenous ghrelin enhance the colonic and gastric manifestations of dextran sodium sulphate-induced colitis in mice. Neurogastroenterol Motil 2009; 21: 59-70.
34. Zhao D, Zhan Y, Zeng H, Moyer MP, Mantzoros CS, Pothoulakis C. Ghrelin stimulates interleukin-8 gene expression through protein kinase C-mediated NF-kappaB pathway in human colonic epithelial cells. J Cell Biochem 2006; 97: 1317-1327.
35. Dembinski A, Warzecha Z, Ceranowicz P, et al. Role of capsaicin-sensitive nerves and histamine H1, H2, and H3 receptors in the gastroprotective effect of histamine against stress ulcers in rats. Eur J Pharmacol 2005; 508: 211-221.
36. Warzecha Z, Dembinski A, Brzozowski T, et al. Gastroprotective effect of histamine and acid secretion on ammonia-induced gastric lesions in rats. Scand J Gastroenterol 2000; 35: 916-924.
37. Bradley PP, Priebat DA, Christensen RD, Rothstein G. Measurement of cutaneous inflammation: estimation of neutrophil content with an enzyme marker. J Invest Dermatol 1982; 78: 206-209.
38. Dembinski A, Warzecha Z, Konturek SJ, et al. Extract of grapefruit-seed reduces acute pancreatitis induced by ischemia/reperfusion in rats: possible implication of tissue antioxidants. J Physiol Pharmacol 2004; 55: 811-821.
39. Vilaseca J, Salas A, Guarner F, Rodriguez R, Martinez M, Malagelada JR. Dietary fish oil reduces progression of chronic inflammatory lesions in a rat model of granulomatous colitis. Gut 1990; 31: 539-544.
40. Hellmich MR, Evers BM. Regulation of gastrointestinal normal cell growth. In: Physiology of the Gastrointestinal Tract, Johnson LR (ed.) Amsterdam - Boston - Heildelberg, Elsevier Academic Press, 2006, pp. 435-458.
41. Greant P, Delvaux G, Willems G. Influence of stress on epithelial cell proliferation in the gut mucosa of rats. Digestion 1988; 40: 212-218.
42. Hall PA, Coates PJ, Ansari B, Hopwood D. Regulation of cell number in the mammalian gastrointestinal tract: the importance of apoptosis. J Cell Sci 1994; 107: 3569-3577.
43. Konturek SJ, Brzozowski T, Dembinski A, Warzecha Z, Konturek PK, Yanaihara N. Interaction of growth hormone- releasing factor and somatostatin on ulcer healing and mucosal growth in rats: role of gastrin and epidermal growth factor. Digestion 1988; 41: 121-128.
44. Konturek SJ, Dembinski A, Warzecha Z, Brzozowski T, Gregory H. Role of epidermal growth factor in healing of chronic gastroduodenal ulcers in rats. Gastroenterology 1988; 94: 1300-1307.
45. Brzozowski T, Konturek PC, Konturek SJ, et al. Effect of local application of growth factors on gastric ulcer healing and mucosal expression of cyclooxygenase-1 and -2. Digestion 2001; 64: 15-29.
46. Beckert S, Class N, Farrahi F, Coerper S. Growth hormone enhances gastric ulcer healing in rats. Med Sci Monit 2004; 10: BR255-BR258.
47. Podolsky DK. Regulation of intestinal epithelial proliferation: a few answers, many questions. Am J Physiol 1993; 264: G179-G186.
48. Sorbye H, Svanes K. The role of blood flow in gastric mucosal defence, damage and healing. Dig Dis 1994; 12: 305-317.
49. Orlando RC. The integrity of the esophageal mucosa. Balance between offensive and defensive mechanisms. Best Pract Res Clin Gastroenterol 2010; 24: 873-882.
50. Leung FW, Reedy TJ, Van Deventer GM, Guth PH. Reduction in index of oxygen saturation at margin of active duodenal ulcers may lead to slow healing. Dig Dis Sci 1989; 34: 417-423.
51. Leung FW, Su KC, Pique JM, Thiefin G, Passaro E, Jr, Guth PH. Superior mesenteric artery is more important than inferior mesenteric artery in maintaining colonic mucosal perfusion and integrity in rats. Dig Dis Sci 1992; 37: 1329-1335.
52. Warzecha W, Dembinski A, Brzozowski T, et al. Histamine in stress ulcer prophylaxis in rats. J Physiol Pharmacol 2001; 52: 407-421.
53. West SD, Helmer KS, Chang LK, Cui Y, Greeley GH, Mercer DW. Cholecystokinin secretagogue-induced gastroprotection: role of nitric oxide and blood flow. Am J Physiol Gastrointest Liver Physiol 2003; 284: G399-G410.
54. Dinarello CA. Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol 2009; 27: 519-550.
55. Garlanda C, Dinarello CA, Mantovani A. The interleukin-1 family: back to the future. Immunity 2013; 39: 1003-1018.
56. Norman J, Franz M, Messina J, et al. Interleukin-1 receptor antagonist decreases severity of experimental acute pancreatitis. Surgery 1995; 117: 648-655.
57. Dinarello CA. A clinical perspective of IL-1β as the gatekeeper of inflammation. Eur J Immunol 2011; 41: 1203-1217.
58. Dinarello CA, Simon A, van der Meer JW. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov 2012; 11: 633-652.
59. De Koning HD, Schalkwijk J, van der Ven-Jongekrijg J., Stoffels M, van der Meer JW, Simon A. Sustained efficacy of the monoclonal anti-interleukin-1 beta antibody canakinumab in a 9-month trial in Schnitzler’s syndrome. Ann Rheum Dis 2013; 72: 1634-1638.
60. Herlin T, Fiirgaard B, Bjerre M, et al. Efficacy of anti-IL-1 treatment in Majeed syndrome. Ann Rheum Dis 2013; 72: 410-413.
61. Mullane KM, Kraemer R, Smith B. Myeloperoxidase activity as a quantitative assessment of neutrophil infiltration into ischemic myocardium. J Pharmacol Methods 1985; 14: 157-167.
62. Barone FC, Hillegass LM, Price WJ, et al. Polymorphonuclear leukocyte infiltration into cerebral focal ischemic tissue: myeloperoxidase activity assay and histologic verification. J Neurosci Res 1991; 29: 336-345.
63. Klebanoff SJ. Myeloperoxidase: friend and foe. J Leukoc Biol 2005; 77: 598-625.
64. Romero FJ, Bosch-Morell F, Romero MJ, et al. Lipid peroxidation products and antioxidants in human disease. Environ Health Perspect 1998; 106 (Suppl. 5): 1229-1234.
65. Kwiecien S, Jasnos K, Magierowski M, et al. Lipid peroxidation, reactive oxygen species and antioxidative factors in the pathogenesis of gastric mucosal lesions and mechanism of protection against oxidative stress - induced gastric injury. J Physiol Pharmacol 2014; 65: 613-622.
66. Parks DA. Oxygen radicals: mediators of gastrointestinal pathophysiology. Gut 1989; 30: 293-298.
67. Pohle T, Brzozowski T, Becker JC, et al. Role of reactive oxygen metabolites in aspirin-induced gastric damage in humans: gastroprotection by vitamin C. Aliment Pharmacol Ther 2001; 15: 677-687.
68. Kwiecien S, Pawlik MW, Brzozowski T, et al. Nitric oxide (NO)-releasing aspirin and (NO) donors in protection of gastric mucosa against stress. J Physiol Pharmacol 2008; 59 (Suppl. 2): 103-115.
69. Zhu H, Li YR. Oxidative stress and redox signaling mechanisms of inflammatory bowel disease: updated experimental and clinical evidence. Exp Biol Med (Maywood) 2012; 237: 474-480
70. Evans MD, Cooke MS. Factors contributing to the outcome of oxidative damage to nucleic acids. BioEssays 2004; 26: 533-542.